CBD anxiety trial for brain cancer patients ends early

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documentation of newly diagnosed glioblastoma, evidenced by neuropathology report and based on World Health Organization (WHO) 2021 classification, and who are to undergo SOC (\~ 6 weeks of treatment) with radiation and temozolomide (patients using Optune may be included). * Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. * Fluent in English. * Endorses at least moderate levels of anxiety (on the BAI or OASIS) at the screening visit * Stable medication/psychotherapy regimens for at least 1 month prior to starting the study (excluding new glioblastoma treatment-related medications or radiation). * Karnofsky Performance Scale (KPS) of 60 or higher. Exclusion Criteria: * Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. * Presence of a condition or abnormality that in the opinion of the Investigators would compromise the safety of the patient or the quality of the data. * Current substance use disorder, psychotic disorder, bipolar disorder, or eating disorder. * Current use of recreational cannabis, medical cannabis, or hemp-derived cannabinoid products more frequently than 1x/month; positive urine delta-9 tetrahydrocannabinol (THC) test. * Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease. * Current use of valproate (due to potential for drug-drug interactions). * Currently enrolled in other research studies or clinical trials involving therapeutic interventions. * Subjects with serum transaminase (ALT, AST, and total bilirubin) levels \>3 times upper limit of normal (UNL) \<24 hours prior to day 1 of treatment. * Contraindication to MRI such as non-MR conditional medical devices or ferrous retained foreign bodies.